MedTrace Logo

Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).

NCT04441385 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-03-11

No results posted yet for this study

Summary

This is a bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (COVID-19).

Conditions

Interventions

DRUG

Maraviroc 300 mg

Patients will receive maraviroc 300 mg twice daily for 14 days

OTHER

Standard care therapy

Subjects randomized to control group will be on standard care treatment according to the Ministry of Health and Local Guidelines and Protocols.

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • ViiV Healthcare

    collaborator INDUSTRY

  • Hospital Universitario Infanta Leonor

    lead OTHER

Principal Investigators

  • Víctor Domínguez, MD · Hospital Universitario Infanta Leonor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-26
Primary Completion
2021-02-08
Completion
2021-02-08

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04441385 on ClinicalTrials.gov